2007
The risk of renal impairment in hormone‐refractory prostate cancer patients with bone metastases treated with zoledronic acid
Oh W, Proctor K, Nakabayashi M, Evan C, Tormey L, Daskivich T, Antràs L, Smith M, Neary M, Duh M. The risk of renal impairment in hormone‐refractory prostate cancer patients with bone metastases treated with zoledronic acid. Cancer 2007, 109: 1090-1096. PMID: 17311345, DOI: 10.1002/cncr.22504.Peer-Reviewed Original ResearchConceptsRisk of renal impairmentHormone-refractory prostate cancerRenal impairmentZoledronic acidHormone-refractory prostate cancer patientsAssociated with renal toxicityHistory of renal diseaseZoledronic acid initiatorsTreat bone metastasesZoledronic acid therapyComprehensive medical record reviewProstate cancer patientsBaseline creatinine valuesTertiary oncology centerCox proportional hazards modelsMedical record reviewProportional hazards modelAndersen-Gill extensionPamidronate useRisk factor analysisBone metastasesPamidronate treatmentProstate cancerOutpatient clinic settingRenal toxicity
2003
Low Estrogen and High Parathyroid Hormone-Related Peptide Levels Contribute to Accelerated Bone Resorption and Bone Loss in Lactating Mice
VanHouten JN, Wysolmerski JJ. Low Estrogen and High Parathyroid Hormone-Related Peptide Levels Contribute to Accelerated Bone Resorption and Bone Loss in Lactating Mice. Endocrinology 2003, 144: 5521-5529. PMID: 14500568, DOI: 10.1210/en.2003-0892.Peer-Reviewed Original ResearchConceptsBone lossBone mineral densityBone resorptionMineral densityDual-energy X-ray absorptiometryBone resorption markersX-ray absorptiometryRegulation of calciumAge-matched virginsPamidronate treatmentPTHrP levelsResorption markersLow estrogenEstrogen deficiencyBone turnoverEstrogen levelsPregnant miceBone metabolismBone massPeptide levelsSkeletal metabolismTotal bodyBone volumeCalcium homeostasisBiochemical markers
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply